48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 80.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,736 shares of the company’s stock after selling 48,108 shares during the period. Squarepoint Ops LLC’s holdings in Contineum Therapeutics were worth $192,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Royal Bank of Canada raised its position in shares of Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after acquiring an additional 2,454 shares in the last quarter. Cannon Global Investment Management LLC acquired a new position in Contineum Therapeutics in the first quarter worth $170,000. Independent Financial Group LLC bought a new stake in Contineum Therapeutics during the first quarter valued at $353,000. Seven Fleet Capital Management LP bought a new stake in Contineum Therapeutics during the first quarter valued at $353,000. Finally, Bank of America Corp DE raised its holdings in shares of Contineum Therapeutics by 411.9% during the first quarter. Bank of America Corp DE now owns 47,449 shares of the company’s stock worth $620,000 after purchasing an additional 38,180 shares during the period.

Analyst Upgrades and Downgrades A number of research analysts have recently issued reports on CTNM shares. Wall Street Zen downgraded shares of Contineum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Royal Bank Of Canada boosted their price objective on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Friday, July 17th. JonesTrading cut their target price on shares of Contineum Therapeutics from $26.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday, September 15th. Finally, Robert W. Baird decreased their target price on Contineum Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, September 15th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Contineum Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

Contineum Therapeutics Stock Performance CTNM stock opened at $12.49 on Friday. Contineum Therapeutics, Inc. has a 1 year low of $8.60 and a 1 year high of $17.78. The stock has a market capitalization of $469.87 million, a price-to-earnings ratio of -7.22 and a beta of 0.75. The stock’s fifty day moving average is $15.11 and its two-hundred day moving average is $13.96.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. As a group, analysts predict that Contineum Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.

Contineum Therapeutics Company Profile (Free Report) Contineum Therapeutics, formerly known as Pipeline Therapeutics, is a clinical-stage biopharmaceutical comp...